- $211.61m
- $223.26m
- $53.84m
- 89
- 24
- 98
- 81
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 27.43 | ||
PEG Ratio (f) | 1.76 | ||
EPS Growth (f) | 18.5% | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 6.65 | ||
Price to Tang. Book | 6.66 | ||
Price to Free Cashflow | 129.27 | ||
Price to Sales | 3.47 | ||
EV to EBITDA | 19.45 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 23.75% | ||
Return on Equity | 21.22% | ||
Operating Margin | 16.83% |
Financial Summary
Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 34.83 | 38.03 | 42.04 | 46.09 | 53.84 | 67.9 | 70 | 14.66% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | +55.71 | +4.65 | -22.02 | +59.12 | -69.38 | +286.17 | +3.48 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Pro-Dex, Inc. specializes in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial markets. The Company has patented adoptive torque-limiting software and sealing solutions, which appeal to its customers, primarily medical device distributors. It also manufactures and sells rotary air motors to a range of industries. The Company’s medical device products utilize designs developed by it primarily under development and supply agreements and are machined in its Irvine, California facility, and assembled in its Tustin, California facility, as are its rotary air motors. Its medical device products are sold primarily to original equipment manufacturers and its air motors are sold primarily to a range of distributors and end users. It has an approximately 25,000 square foot industrial building in Tustin, California (the Franklin Property).
Directors
- Nicholas Swenson NEC (53)
- Richard Van Kirk PRE (61)
- Alisha Charlton CFO (52)
- Raymond Cabillot IND (58)
- Angelita Domingo IND (49)
- William Farrell IND (48)
- David Hovda IND (59)
- Katrina Philp IND (36)
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 26th, 1994
- Public Since
- May 31st, 1994
- No. of Shareholders
- 122
- No. of Employees
- 148
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market
- Shares in Issue
- 3,261,043

- Address
- 2361 McGaw Ave, IRVINE, 92614
- Web
- https://www.pro-dex.com/
- Phone
- +1 9497693200
- Auditors
- MOSS ADAMS LLP
Upcoming Events for PDEX
Q4 2025 Pro-Dex Inc Earnings Release
Similar to PDEX
Accelerate Diagnostics
NASDAQ Capital Market
Adagio Medical Holdings
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
FAQ
As of Today at 22:45 UTC, shares in Pro-Dex are trading at $64.89. This share price information is delayed by 15 minutes.
Shares in Pro-Dex last closed at $64.89 and the price had moved by +251.52% over the past 365 days. In terms of relative price strength the Pro-Dex share price has outperformed the S&P500 Index by +224.46% over the past year.
The overall consensus recommendation for Pro-Dex is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out morePro-Dex does not currently pay a dividend.
Pro-Dex does not currently pay a dividend.
Pro-Dex does not currently pay a dividend.
To buy shares in Pro-Dex you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $64.89, shares in Pro-Dex had a market capitalisation of $211.61m.
Here are the trading details for Pro-Dex:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: PDEX
Based on an overall assessment of its quality, value and momentum Pro-Dex is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Pro-Dex is $54.00. That is 16.78% below the last closing price of $64.89.
Analysts covering Pro-Dex currently have a consensus Earnings Per Share (EPS) forecast of $2.30 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pro-Dex. Over the past six months, its share price has outperformed the S&P500 Index by +135.27%.
As of the last closing price of $64.89, shares in Pro-Dex were trading +74.26% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Pro-Dex PE ratio based on its reported earnings over the past 12 months is 27.43. The shares last closed at $64.89.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Pro-Dex's management team is headed by:
- Nicholas Swenson - NEC
- Richard Van Kirk - PRE
- Alisha Charlton - CFO
- Raymond Cabillot - IND
- Angelita Domingo - IND
- William Farrell - IND
- David Hovda - IND
- Katrina Philp - IND